NCT01917552招募中3 期
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 870
- 试验地点
- 1
- 主要终点
- recurrence-free survival
研究概览
简要总结
multi-center, prospective, randomized, open-label phase III
详细描述
This is a prospective, randomized, open-label phase III study of adjuvant chemotherapy after curative resection in patients with pathologic stage IB (by AJCC 6th edition) gastric cancer with at least one additional risk factor (additional risk factors for recurrence include age >65 years, male gender, presence of lymphovascular invasion, presence of perineural invasion). The superiority design will compare the efficacy and safety profiles of adjuvant capecitabine (Arm A) versus observation alone (Arm B).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Curatively resected gastric or gastroesophageal junction adenocarcinoma
- •Pathologic stage IB (by AJCC 6th edition) with at least one additional risk factor for recurrence (additional risk factors for recurrence include age >65 years, male gender, presence of lymphovascular invasion, presence of perineural invasion).
- •Age: 18 -74years
- •ECOG performance status: 0-2
- •Adequate bone marrow function (ANC >1,500/uL, Platelets 100,000/uL, and Hb > 8.0 g/dL)
- •Adequate renal function (serum creatinine < 1.5 mg/dL)
- •Adequate hepatic function (bilirubin < 1.5 mg/dL, ALT and AST < 3 times upper limit of normal)
- •Written informed consent
排除标准
- •Pregnant or lactating women.
- •Women of childbearing potential with either a positive pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-child bearing potential.
- •Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study medication and until 3 months after discontinuation of the study medication.
- •Any evidence of metastatic disease (including presence of tumor cells in the ascites).
- •Previous chemotherapy or radiotherapy for the currently treated gastric cancer.
- •No recovery from serious complications of gastrectomy.
- •History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
- •History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
- •Clinically significant (i.e. active) cardiac disease: e.g. unstable angina, symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 6 months.
- •Lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome likely to influence absorption of capecitabine, or inability to take oral medication.
- •Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.
- •Organ allografts requiring immunosuppressive therapy.
- •Received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before randomization.
- •Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or chemically related analogues, such as brivudine.
- •Positive serologic test for HIV
研究组 & 干预措施
capecitabine
Experimental
capecitabine 1250 milligram (mg) / m² po bid (D1-14)
干预措施: capecitabine (Drug)
结局指标
主要结局
recurrence-free survival
时间窗: 8 years
To demonstrate that capecitabine is superior to observation only (control arm) in terms of recurrence-free survival in curatively resected stage IB gastric cancer.
次要结局
- overall survival(8 years)
- Safety profiles(8years)
研究者
Min-Hee Ryu
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer PatientsBreast CancerNCT00130533Spanish Breast Cancer Research Group876
招募中
不适用
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)NeoplasmsKCT0001298Asan Medical Center870
已完成
3 期
A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric CancerGastric CancerNCT02560974Hoffmann-La Roche1,035
已完成
3 期
Capecitabine and Oxaliplatin Adjuvant Study in Stomach CancerStomach NeoplasmsNCT00411229Sanofi1,035
招募中
3 期
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric CancerStomach CancerNCT04135781Zhejiang Cancer Hospital616